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Toll-like receptor 9 (TLR9) is a cellular DNA receptor of the innate immune system. DNA
recognition via TLR9 results in an inflammatory reaction, which eventually also activates
a Th1-biased adaptive immune attack. In addition to cells of the immune system, TLR9
mRNA and protein are also widely expressed in breast cancer cell lines and in clinical
breast cancer specimens. Although synthetic TLR9-ligands induce cancer cell invasion
in vitro, the role of TLR9 in cancer pathophysiology has remained unclear. In the studies
conducted so far, tumor TLR9 expression has been shown to have prognostic significance
only in patients that have triple-negative breast cancer (TNBC). Specifically, high tumorTLR9
expression predicts good prognosis amongTNBC patients. Pre-clinical studies suggest that
TLR9 expression may affect tumor immunophenotype and contribute to the immunogenic
benefit of chemotherapy. In this review, we discuss the possible contribution of tumor
TLR9 to the pathogenesis and treatment responses in breast cancer.
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INTRODUCTION
Toll-like receptor 9 (TLR9) is a DNA receptor that recog-
nizes microbial and vertebrate DNA (1–5). Initially, TLR9 was
thought to recognize specifically the CpG sequence in DNA (1,
6). The sequence-requirement may, however, be relevant only
for the synthetic, oligonucleotide TLR9-ligands in the phos-
phorothioate backbone, and also CpG sequence-independent
TLR9 activation by DNA has been reported (6–8). Like the
other TLRs that recognize nucleic acids (TLR3, TLRs 7–8, and
TLR13), TLR9 is located at the endoplasmic reticulum in rest-
ing cells (9, 10). When DNA enters the cell, TLR9 translocates
to the endosomal/lysosomal compartment where ligand recog-
nition and binding takes place (9, 11). DNA recognition by
TLR9 initiates a downstream signaling cascade, which includes
the adaptor molecule MyD88 (12, 13). As an effector of the
innate immune system, stimulation of TLR9 induces a NF-κB-
mediated rapid inflammation, characterized by increased expres-
sion of various interleukins and cytokines. A common feature
for the nucleotide-sensing TLRs is the induction of both antivi-
ral and antitumoral type I interferons (IFNs) from plasmocy-
toid dendritic cells (pDCs) (14). Eventually, this inflammation
also activates the adaptive immune system, which then results
in the clearance of the invading pathogens and the infected
cells (2, 15). A similar inflammatory response, mediated via
TLRs, also takes place during sterile tissue damage (16–19). In
addition to DNA, other biological molecules have also been
suggested to induce TLR9-mediated responses. Such molecules
include the malaria pigment hemozoin and histone proteins (17,
20–22). TLR9 was recently shown also to recognize RNA–DNA
hybrids (23).
TLR9 EXPRESSION IN BREAST CANCER
Toll-like receptor 9 expression has been detected in cells of breast
milk (TLR9 mRNA) and also in normal epithelial cells of the mam-
mary gland (TLR9 protein) (24, 25). TLR9 mRNA and protein
are also widely expressed in various human cancer-cell lines as
well as in clinical cancer specimens, including breast, prostate,
brain, gastric, renal cell carcinoma, and esophageal tumors (24,
26–33). Specifically in breast cancer, TLR9 protein expression has
been detected both in the epithelial cancer cells as well as in the
fibroblast-like cells associated with the tumors (24, 26, 29, 34).
Consistent with the endosomal/lysosomal localization of TLR9 at
the subcellular level, in breast cancer cells in vitro, TLR9 appeared
punctate in intracellular fluorescence staining, located especially
in the perinuclear region, where these organelles are located (35).
Of the five human TLR9 isoforms (A–E), mRNA expression of the
TLR9 A and B isoforms has been studied and detected in breast
cancer specimens (36, 37).
TLR9 AS A PROGNOSTIC FACTOR IN BREAST CANCER
The prognostic significance of TLR9 in cancers appears to be
bimodal. In some cancers, such as glioma, prostate cancer, and
esophageal adenocarcinoma, high tumor TLR9 expression has
been associated with poor survival whereas in others, such as
triple-negative breast cancer (TNBC) or renal cell carcinoma, low
tumor TLR9 expression upon diagnosis predicts poor prognosis
(27, 30, 32, 33, 38, 39). We demonstrated recently that although
widely expressed in all clinical subtypes of breast cancer, TLR9
expression has significant, prognostic significance only in TNBC
that lack the expression of estrogen (ER), progesterone (PR), and
HER2 receptors. More specifically, low tumor TLR9 expression
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upon diagnosis was associated with a significantly shortened
disease-free-specific survival (29, 32). Furthermore, although we
demonstrated that low-TLR9–TNBC cells become highly invasive
in hypoxic conditions, it is currently unclear whether this mecha-
nism contributes to the poor survival of the breast cancer patients
that have hypoxic, low-TLR9–TNBC tumors. The mechanism for
the increased invasion in hypoxia when TLR9 is absent is also not
known (32). In addition to the actual tumor cells, the TLR9 expres-
sion status of tumor-associated fibroblast-like cells has also been
shown to be of prognostic value in breast cancer. In this context,
high TLR9 expression was associated with better prognosis (34).
This study did not, however, assess triple-negative status of the
cancers, and the exclusion of metastatic and neoadjuvant-treated
patients probably counter selected against patients of the TNBC
subtype.
EFFECTS OF TLR9 STIMULATION ON CELLULAR INVASION
Synthetic TLR9-ligands, the CpG sequence-containing oligonu-
cleotides (CpG–ODNs, such as ODN M362) that mimic bacterial
DNA, are strong inducers of inflammation in cells of the immune
system (40, 41). These oligonucleotides mimic bacterial DNA
based on their high CpG content and unmethylated cytosines.
CpG–ODNs are taken up into cells via DEC-205, a multilectin
cell surface receptor, which is expressed in various cell types (42).
These same compounds induce cellular invasion in macrophages,
mesenchymal stem cells, and in cancer cells of various origins
in vitro (24, 28, 43, 44). In breast cancer cells, such synthetic TLR9
ligand-induced invasion has been detected both in ER-positive
and ER-negative breast cancer cells (24, 28, 35). This invasive
effect is mediated via TLR9, and it is blocked by chloroquine,
an inhibitor of endosomal acidification and an inhibitor of TLR9
signaling. Downstream of TLR9, such invasion is mediated via
TRAF6, but not MyD88 (24, 28, 35). At the proteolytic level,
CpG–ODN-induced invasion is associated with down-regulation
of tissue inhibitor of matrix metalloproteinases-3 (TIMP-3) and
activation of matrix metalloproteinase-13 (MMP-13) (24, 28, 35,
44). Interestingly, although methylation of cytosines in CpGs has
been shown to decrease their pro-inflammatory effects, the inva-
sive effects of these molecules are independent of their methylation
status (35, 40, 45). CpG–ODNs can form various secondary struc-
tures, including homopolymer duplexes and hairpins, containing
stem loop structures. The stem loop secondary structure appears
important for the invasive effects of the CpG–ODN (35). Fur-
thermore, the invasive effects can also be seen with non-CpG
sequence-containing ODNs that in inflammatory experiments act
as TLR9 antagonists (24, 46). The synthetic, phosphorothioate-
backbone-modified CpG–ODNs do not exist in nature. Thus,
for this invasion to have physiological significance, it would have
to be caused also by natural DNA in the phosphodiester back-
bone. In prostate cancer cell lines and in gastrointestinal cancer
cell lines, bacterial DNA (purified from Escherichia coli or Heli-
cobacter pylori, respectively) also has similar, stimulatory effects
on invasion (28, 43). Whether microbe-derived DNA similarly
induces invasion in breast cancer cells is not known. We, how-
ever, demonstrated recently that self-DNA, which is derived from
chemotherapy-treated, dead cancer cells is rapidly taken up into
surviving cancer cells, where it serves as an invasion-inducing
TLR9 ligand (47). This cellular uptake is possibly endocytosis
or pinocytosis-mediated, since fluorescently labeled, dead cancer-
cell-derived DNA, which was added to cell culture medium, was
seen inside the recipient cells rapidly, within 15 min. However,
similar to other reported TLR9-mediated effects of cell-derived
self-DNA, complex formation of such cell-derived DNAs with the
cationic antimicrobial peptide LL-37 enhanced DNA uptake into
viable breast cancer cells, and was a requirement for the invasion-
inducing effects (47, 48). This scenario may be physiologically
relevant since LL-37 is expressed also in breast cancers (49, 50).
Interestingly, the effects of cell-DNA on invasion are mediated via
cathepsins and surprisingly, not via MMPs, which are the media-
tors for CpG–ODN-induced invasion (44, 47, 51, 52). DNA that
was derived from intact, proliferating cancer cells did not induce
invasion. This suggests that the invasive effect requires a certain
DNA-structure, either alone or in complex with LL-37. Such DNA-
structures could possibly be formed upon DNA degradation by
nucleases. Whether self-DNA-induced and TLR9-mediated can-
cer cell invasion takes place in vivo in breast or any cancer is
currently unknown. In principle, however, such DNA-induced
and TLR9-mediated cancer cell invasion could represent a novel
mechanism of treatment resistance. Since tumor growth is the
sum of local proliferation and local invasion, such treatment resis-
tance could theoretically manifest as no change or even increase in
tumor size despite treatment. Finally, TLR9 appears to have also
ligand-independent invasive activity. Down-regulation of TLR9
in MDA-MB-231 breast cancer cells through siRNA results in
decreased in vitro invasion in the absence of exogenous DNA.
The decreased invasion of the TLR9 siRNA cells was associated
with decreased MMP activity and increased expression of TIMP-3
(32). Similar effects were also detected by TLR9 siRNA in brain
cancer cells in vitro (53). These TLR9 expression-induced changes
in the cellular invasive machinery suggest that TLR9, as a DNA-
binding protein, might also have effects on gene transcription.
TLR9 expression has indeed been detected in the nuclei of renal
cell carcinoma tumor samples (30), but whether or not it can
directly affect gene expression, requires further experimenting.
EFFECTS OF TLR9 STIMULATION ON INFLAMMATION
Toll-like receptor 9 agonists have various well documented pro-
inflammatory effects in cells of the immune system (40, 41, 48,
54). Whether synthetic TLR9 agonists also induce the expres-
sion of inflammatory mediators in breast cancer cells, is not
known. In cells of the immune system, a key characteristic
of the TLR9-induced innate immune response is the promo-
tion of a strong type I T helper cell (Th1) adaptive immune
response. This includes both CD8+ T-cell responses and antigen-
specific antibody responses (55). Since CD8+ T-cells are capable
of immunologic tumor cell destruction, CpG–ODNs have been
tested both as monotherapy and as an adjuvant for cancer vac-
cines, against various cancer types in pre-clinical cancer models,
including breast cancer (55). In mouse models of breast cancer,
CpG–ODN treatment resulted in the eradication of orthotopic
tumors (56, 57). CpG–ODN treatment also induced an immuno-
logic memory against tumor challenge, which was associated with
an up-regulation of IFN-γ-positive CD4+ and CD8+ T-cells (56,
57). CpGs, when given as an adjuvant with a peptide vaccine,
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also prevented the formation of spontaneous tumors in a mouse
model of HER2-positive breast cancer (58). Although the direct
growth inhibitory effects of CpG–ODNs on cancer cells are quite
weak in vitro, certain modifications in the CpG structure have
resulted in increased tumor growth inhibition, also in nude mouse
models in vivo, suggesting direct tumor effects of these com-
pounds (24, 59–61). Furthermore, when given in a combination,
the immunomodulatory ODN was also shown to potentiate the
efficacy of trastuzumab,an anti-HER2-antibody, in a mouse model
of breast cancer (59). In conclusion, these pre-clinical experi-
ments suggest that TLR9 ligands can directly inhibit the growth of
breast cancer cells in vitro and in vivo, and they can enhance anti-
tumor immunity, possibly via inducing a Th1 adaptive immune
response. These studies have not, however, addressed the role of
TLR9 expression in tumors vs. host in these responses. Despite the
successful pre-clinical results, CpG treatment has demonstrated
anti-tumor activity only in select patients in clinical trials. There
are, however, no reports on their efficacy in breast cancer tri-
als (55). Finally, the discrepancies between the in vitro-observed,
unwanted tumor invasion-promoting effects and the favorable,
most likely immune system-mediated anti-tumor effects of the
synthetic TLR9-ligands are likely explained by the pharmacokinet-
ics of these compounds. After s.c. and i.v. administration, highest
concentrations of TLR9 ligands are detected in plasma, kidneys,
and organs of the reticuloendothelial system, and much less so in
tumor tissues (59).
Self-DNA has been shown to have TLR9-mediated inflamma-
tory effects in other cell types, especially when complexed with
LL-37, which is expressed in various tissues (16, 48, 52, 62).
We demonstrated recently that self-DNA, which is derived from
doxorubicin-killed breast cancer cells, induces mRNA expression
of various inflammatory mediators in living, TLR9-expressing
cells. Furthermore, while assessing treatment responses to dox-
orubicin in a mouse model of TNBC, we discovered that although
the tumor response to treatment was similar in TLR9 siRNA
and control siRNA TNBC groups, mice bearing TLR9 siRNA
tumors lost significantly less weight than similarly treated mice
with control siRNA tumors. Similar weights of the vehicle-treated
mice suggested to us that TLR9 expression in the tumors may be
an important determinant of chemotherapy-induced inflamma-
tion and activation of anti-tumor immunity (47). Inflammatory
response to chemotherapy is gaining acceptance as an important
mediator of treatment responses to standard cancer therapy (63).
More specifically, we hypothesize that the tumor TLR9-dependent,
post-treatment weight loss is actually a surrogate marker for
self-DNA-induced and TLR9-mediated inflammation that takes
place at the tumor site. Such tumor TLR9-mediated inflamma-
tion might then amplify the anti-tumor immune response, erad-
icate microscopic disease and through this mechanism, translate
into cure (47). We predict that the lack of such immunogenic
effect in tumors that have low-TLR9 expression indeed con-
tributes to the described poor disease-specific survival in triple-
negative disease (32). This hypothesis requires a detailed analysis
of tumor TLR9-dependent immune response to chemotherapy
in immune-competent pre-clinical cancer models. However, if
true, it would mean that patients with low-TLR9–TNBC could
especially benefit from adjuvant cancer immunotherapy. It is also
possible that TLR9 expression changes tumor immunophenotype
independent of treatment and this aspect also requires further
investigation.
TLR9 REGULATION IN BREAST CANCER
Several cancer-associated viruses have been shown to down-
regulate TLR9 expression through their oncoproteins. For exam-
ple, human papillomavirus (HPV), Epstein–Barr virus, and
hepatitis B virus inhibit the expression and impair the function of
TLR9 in infected target cells (64–66). Patients with chronic hepati-
tis B virus have decreased levels of TLR9 mRNA in peripheral
blood mononuclear cells (67). The Merkel cell polyomavirus large
T antigen down-regulates TLR9 expression in epithelial cells and
in cells derived from Merkel cell carcinomas (68). For the HPV16,
the mechanism behind TLR9 suppression was recently shown to
involve the viral oncoprotein E7-induced formation of transcrip-
tional inhibitory complex that includes NF-κB p50–p65, ERα, and
chromatin modifying enzymes. This complex induces epigenetic
changes at the TLR9 promoter area (69). It is likely that these viral
effects on TLR9 expression and function play an important role
in viral persistence, through inhibition of host immune responses
(64, 65, 67, 70, 71). Nevertheless, also opposite effects on microbial
TLR9 regulation have been suggested (72, 73). Although breast
cancer is not currently considered to have viral etiology, several
viruses, including human papilloma viruses, have been detected
in normal and cancerous human breast tissues (74–77). Whether
or not these viral effects have a role in breast cancer development
or pathophysiology is currently unknown.
Tumor microenvironment oxygen concentration is also an
important regulator of TLRs. Similar with the effects of hypoxia
on other TLRs in other cell types, hypoxia also up-regulates TLR9
expression in breast cancer cells in vitro and in orthotopic breast
tumors in vivo (32, 51, 78). These hypoxia effects on TLR9 mRNA
and protein expression were mediated via HIF-1α in breast cancer
cells in vitro (32). TNBCs are typically hypoxic (79). Therefore,
understanding the mechanism on why tumor TLR9 expression
levels remain low despite hypoxia in some TNBCs might open
novel therapeutic possibilities that might also apply to renal cell
carcinoma (30). It was also demonstrated recently that TLR9
expression is under the control of the circadian molecular clock
(80). The significance of this finding for breast and other cancers
is currently open.
Although TLR9 is expressed in all clinically relevant subtypes
of breast cancer, we and others have discovered that there is an
inverse correlation between tumor TLR9 and ER expression: ER-
positive breast cancers have significantly lower levels of TLR9
expression, as compared with TNBCs (26, 29, 32, 36). The basal
TLR9 expression is also significantly lower in human ER-positive
breast cancer cells, as compared with human ER-negative breast
cancer cell lines in vitro. Furthermore, transfection of ERα cDNA
into TNBC cells suppresses TLR9 expression of the recipient cells
(36). Both estradiol and testosterone induced TLR9 expression via
their cognate receptors in breast cancer cells in vitro. Testosterone
also augmented the pro-invasive effects of CpG–ODNs. Finally,
bicalutamide, a commonly used hormonal treatment in prostate
cancer, increased TLR9 expression in ER-positive breast cancer
cells (36). This effect of bicalutamide on TLR9 expression might
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be of therapeutic interest since a proportion of TNBC tumors
express the androgen receptor that bicalutamide targets (81).
TLR9 POLYMORPHISM IN BREAST CANCER
The TLR9 gene is located on human chromosome 3 (82). Although
TLR9 gene polymorphisms have been studied in other diseases,
including infectious and autoimmune diseases and some can-
cers, very little is known about TLR9 gene polymorphism in
breast cancer (83–86). A study conducted by Resler and cowork-
ers using over 800 case and control samples, found that the single
nucleotide polymorphism (SNP, rs352140) in TLR9, which does
not alter protein amino acid sequence but might alter protein
function or stability, was associated with breast cancer risk (OR
0.85, 95% CI 0.74–0.97) (87). The patients in this study were all
post-menopausal (65–79 years) and 80% of the cases had hormone
receptor-positive breast cancer. These results were in contrast to
those of Etokebe et al., who found no association in the same TLR9
SNP with breast cancer risk in a small Croatian cohort, consisting
of 130 breast cancer cases and 101 controls (88).
CONCLUSION
Although TLR9 is widely expressed in breast cancers, it appears
that tumor TLR9 expression has prognostic significance only in
TNBC. Especially, TNBC patients that have low tumor TLR9
expression upon diagnosis have a significantly shortened disease-
specific survival, as compared with TNBC patients that have high
tumor TLR9 expression. These findings, however, need to be
repeated in larger and more diverse patient populations. TNBC
tumors are typically hypoxic and low oxygen concentrations up-
regulate TLR9 expression in TNBC cells in pre-clinical models.
Understanding why TLR9 expression levels remain low in some
TNBC tumors in the hypoxic tumor microenvironment might
reveal novel therapeutic opportunities. It has been demonstrated
recently that viral oncoproteins down-regulate TLR9 expression
in various cancer tissues. Although breast cancer is not currently
considered to have viral etiology, various viruses known to be capa-
ble of down-regulating TLR9 expression have also been detected
in breast cancers. The contribution of these viral infections to
low tumor TLR9 status in TNBC should therefore be addressed
in future studies. Finally, the mechanisms how the lack of tumor
TLR9 expression results in poor prognosis are unknown. Studies
from pre-clinical TNBC models suggest that tumor TLR9 expres-
sion might affect tumor immunophenotype or be required for
chemotherapy-induced anti-tumor immune response. If this is the
case, then patients with low-TLR9–TNBC tumors might benefit
from anti-cancer immune therapy. The specificity of the immune
therapy requires, however, a clear understanding of how TLR9
expression affects tumor immunity. Synthetic TLR9 agonists,
CpG–ODNs have demonstrated promising direct and immune
system-mediated anti-cancer effects against breast cancer in pre-
clinical models but they have not been studied in clinical breast
cancer trials. It is clear that synthetic CpG–ODNs induce cancer-
cell invasion in vitro. Whether this finding is relevant for the clinical
situation, where such agonists are given in order to boost the anti-
tumor immune response, remains to be resolved. Finally, aiming
to increase tumor TLR9 expression prior to chemotherapy should
be considered a therapeutic opportunity in the TNBC patients that
have low tumor TLR9.
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